AllJournalThesisConferenceNewspaperPatentStandardYear BookBook|ResearcherProject
all languages  Chinese Only  Other Languages
Author:Sokol Lubomir , Sotomayor Eduardo M
Data Source:[J].BMC cancer(IF 3.333), 2014, Vol.14, pp.900PubMed
Abstract:Malignant bone lymphoma can be classified as primary (PBL) or secondary (SBL) bone lymphoma. However, the clinico-pathological characteristics and prognostic factors of PBL versus SBL have not yet been well defined. Whether lymphoma with multifocal bone involvement should be cons...
Author:Sokol Lubomir , Balser Barbara ...
Data Source:[J].Journal of hematology & oncology(IF 4.458), 2016, Vol.9 (1), pp.22PubMed
Abstract:Achievement of durable responses in patients with relapsed/refractory peripheral T cell lymphoma (PTCL) is challenging with current therapies, and there are few data regarding the potential benefits of continuing treatment in patients with the best response of stable disease...
Author:Sokol Lubomir , Greenwood Matthew ...
Data Source:[J].Journal of hematology & oncology(IF 4.458), 2014, Vol.7, pp.11PubMed
Abstract:Romidepsin is a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma who have received ≥ 1 prior systemic therapy and patients with p...
Author:... Wei Sheng , Sokol Lubomir , List Alan F
Data Source:[J].PloS one(IF 3.73), 2014, Vol.9 (12), pp.e114249PubMed
Abstract:Anemia remains the principal management challenge for patients with lower risk Myelodysplastic Syndromes (MDS). Despite appropriate cytokine production and cellular receptor display, erythropoietin receptor (EpoR) signaling is impaired. We reported that EpoR signaling is dependen...
Author:Sokol Lubomir , Usmani Saad Z ...
Data Source:[J].Clinical cancer research : an official journal of the American Association for Cancer Research(IF 7.837), 2013, Vol.19 (13), pp.3659-70PubMed
Abstract:To evaluate the safety and pharmacokinetics of siltuximab, an anti-interleukin-6 chimeric monoclonal antibody (mAb) in patients with B-cell non-Hodgkin lymphoma (NHL), multiple myeloma, or Castleman disease.;;In an open-label, dose-finding, 7 cohort, phase I study, patients with ...
Author:Sokol Lubomir , Solé Francesc ...
Data Source:[J].Oncotarget(IF 6.636), 2015, Vol.6 (33), pp.34437-45PubMed
Abstract:P53 is a key regulator of many cellular processes and is negatively regulated by the human homolog of murine double minute-2 (MDM2) E3 ubiquitin ligase. Single nucleotide polymorphisms (SNPs) of either gene alone, and in combination, are linked to cancer susceptibility, disease p...
Author:Kelling Matthew , Sokol Lubomir , Dalia Samir
Data Source:[J].Cancer control : journal of the Moffitt Cancer Center, 2018, Vol.25 (1), pp.1073274818767879PubMed
Abstract:Chronic active hepatitis B infection (HBV) has been implicated in lymphomagenesis of non-Hodgkin lymphoma (NHL). Treatment of cancer including NHL with chemotherapy or immunotherapy can lead to HBV reactivation in previously infected patients. Serological testing of HBV prior to ...
Author:Sokol Lubomir , Chavez Julio C
Data Source:[J].Cancer control : journal of the Moffitt Cancer Center, 2018, Vol.25 (1), pp.1073274818778256PubMed
Abstract:Primary gastric lymphoma (PGL) is the most common extranodal non-Hodgkin lymphoma and represents a wide spectrum of disease, ranging from indolent low-grade marginal zone lymphoma or mucosa-associated lymphoid tissue (MALT) lymphoma to aggressive diffuse large B-cell lymphoma. Th...
Author:... Anasetti Claudio , Sokol Lubomir , Hussaini Mohammad O
Data Source:[J].Case reports in hematology, 2018, Vol.2018, pp.9191582PubMed
Abstract:Nonhepatosplenic/noncutaneous γδ peripheral T-cell lymphoma (NHNC γδ PTCL) represents a miscellaneous group of unrelated T-cell lymphomas of which only isolated cases have been reported. We describe two cases of transformation from T-lymphoblastic leukemia/lymphoma to N...

Being retrieved, please wait for a moment...

International Cooperation:cnki.scholar@cnki.net, +86-10-82896619   Feedback:scholar@cnki.net

×